Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial

Shuya Li, Xuechun Wang, Baoyu Feng, Hao Li, Yongjun Wang

Open source

DOI
10.1136/svn-2025-004582
Published
2025-12-04
Container
Stroke and Vascular Neurology
Publisher
BMJ
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/svn-2025-004582,
  title = {Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial},
  author = {Shuya Li and Xuechun Wang and Baoyu Feng and Hao Li and Yongjun Wang},
  year = {2025},
  journal = {Stroke and Vascular Neurology},
  doi = {10.1136/svn-2025-004582},
  url = {https://doi.org/10.1136/svn-2025-004582}
}

RIS

TY  - JOUR
TI  - Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial
AU  - Shuya Li
AU  - Xuechun Wang
AU  - Baoyu Feng
AU  - Hao Li
AU  - Yongjun Wang
PY  - 2025
JO  - Stroke and Vascular Neurology
DO  - 10.1136/svn-2025-004582
UR  - https://doi.org/10.1136/svn-2025-004582
ER  - 

APA

Li, S., Wang, X., Feng, B., Li, H., & Wang, Y. (2025). Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial. Stroke and Vascular Neurology. https://doi.org/10.1136/svn-2025-004582

Source records